ArticleMolecular biology reports2025
The therapeutic role of Coccinia grandis in flavor-enhancing high-lipid diet-induced chronic kidney disease: a dual role of NF-kB and TGF-β/smad in renal fibrosis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCoccinia grandis (CG), a plant used as traditional medicine, possesses antioxidant, anti-inflammatory, and anti-fibrotic activities. Chronic kidney disease (CKD) and renal fibrosis are public health issues, further promoted by monosodium glutamate in high-lipid diets (MH) via oxidative stress and inflammation. CG could potentially alleviate MH-induced CKD by modulating cell signaling. The purpose of this study is to hypothesize that CG, with known anti-inflammatory and antioxidant properties, might counteract MH-induced kidney dysfunction through its putative modulation of the signaling pathway. METHODS AND
resultsMale Wistar rats were administered ethanol extracts of CG leaves (etCGL) with or without MH for 28 days, and their effects on renal homeostasis, inflammation, and fibrosis were assessed. Finally, the major components of the MH and CG were docked to identify a better docking affinity and a stable interaction of the ligand with its receptor, highlighting the therapeutic target specificity. etCGL effectively improved kidney function, prevented oxidative stress, and decreased pro-inflammatory cytokines (TGF-β, collagen) in rats fed with MH. Histology demonstrated restored renal structure and minimal fibrosis in the MH + etCGL-fed group. The renoprotective activities of etCGL with its phytocompounds such as catechin, p-coumaric acid, and naringenin as a composite extract were mediated by inhibiting NF-kB and TGF-β/Smad pathways.
conclusionsTherefore, it can be concluded that CG, with its active compounds, can be a useful dietary approach in MH-associated CKD. Clinical trials across populations would establish the efficacy of etCGL, and understanding its molecular mechanism will be crucial for elucidating the mechanisms of its protective action.
Indexed as
Identifiers
40775474What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.